R&D Trends

DCRI, SAS open heart-disease data to researchers

Monday, May 9, 2016

A new collaboration between the Duke Clinical Research Institute (DCRI) and SAS will give more researchers access to the largest and oldest cardiovascular database in the world. The DCRI and analytics leader SAS will provide researchers worldwide with data management and analytics tools to explore 45 years of cardiovascular patient data collected by the Duke University Health System.

[Read More]

WAVE, Pfizer partner on metabolic diseases

Thursday, May 5, 2016

WAVE Life Sciences has entered into a research, license and option agreement with Pfizer for the potential development of nucleic acid therapies aimed at silencing the underlying causes of debilitating metabolic diseases. The collaboration will focus on genetically defined targets and bring together WAVE’s proprietary stereopure drug development platform, across antisense and RNAi modalities, along with GalNAc and Pfizer’s hepatic targeting technology for enhanced delivery to the liver.

[Read More]

EMD Serono expands biopharmaceutical R&D facility in Massachusetts

Tuesday, May 3, 2016

EMD Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, in North America, has announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

[Read More]

Basilea awarded $100M BARDA contract for ceftobiprole program

Thursday, April 21, 2016

Basilea Pharmaceutica has announced that the Biomedical Advanced Research and Development Authority (BARDA), a division within the U.S. Department of Health and Human Services` Office of the Assistant Secretary for Preparedness and Response, has entered into a contract with Basilea Pharmaceutica International for the clinical phase III development aiming at regulatory approval of Basilea`s broad-spectrum antibiotic ceftobiprole in the U.S.

[Read More]

DNAnexus, Solvebio partner to make genomic data more actionable

Thursday, April 21, 2016

DNAnexus, a cloud-based genome informatics and data management provider, has announced a partnership with SolveBio, a global provider of Genomics Intelligence, to integrate the two platforms and provide seamless access to SolveBio’s curated data and analysis services. Researchers globally will have the ability to move quickly from genomic data analysis to interpretation, freeing up time to focus on generating uniquely actionable biological insights.

[Read More]